SAGE - Sage Therapeutics GAAP EPS of -$3.37 misses by $0.67 revenue of $2.72M misses by $0.45M
2023-11-07 06:32:40 ET
More on Sage Therapeutics
- Sage Therapeutics: Several Neuropsychiatric Disorder Data Readouts In 2024
- Sage Therapeutics: Undeserving Selloff Presents A Buying Opportunity
- Sage Therapeutics Q3 2023 Earnings Preview
- Sage granted FDA orphan tag for Huntington’s disease therapy
- Seeking Alpha’s Quant Rating on Sage Therapeutics
For further details see:
Sage Therapeutics GAAP EPS of -$3.37 misses by $0.67, revenue of $2.72M misses by $0.45M